CAR T-cell therapy made locally for B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CD19-positive lymphoma or B-ALL (certain specific types listed).
- Your cancer has not responded to at least a certain number of prior treatments (or is refractory/progressing).
- You cannot safely get the regular (commercial) CD19 CAR T-cell therapy.
- You must have measurable disease (not full remission) and, for B-ALL, detectable disease on two tests at least 2 weeks apart.
- You must meet basic health checks: age 18–79, heart pumping strength adequate, and able to breathe without extra oxygen at rest.
- You must be able to consent and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests a new CAR T-cell treatment for people with certain blood cancers (like some leukemias and lymphomas) that have not responded to other treatments. It may help even if previous CD19-targeted therapies have stopped working.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.